Leer artículo completo sobre IM Medico
Galyan Bio
http://www.galyan.bio Galyan Bio is developing orally available small molecules for neurodegenerative diseases. We are employing AI-driven de novo drug design methods to id...
Chemotargets y Galyan Bio desarrollan el primer fármaco diseñado con IA para la enfermedad de Huntington
El nuevo tratamiento oral pretende retardar la patología en los pacientes sintomáticos y retrasar la manifestación en los portadores del gen sin síntomas.
Galyan Bio is developing orally available small molecules for neurodegenerative diseases. We are employing AI-driven de novo drug design methods to identify new scaffold for first-in-class clinical candidates. The new treatments interfere in the protein quality control system and are subsequently also useful for healthy aging.
media@galyan.bio
Contacts /
For more information, please contact:
Rohit Shyam
Chief Business Officer